Payment overview · 2025
General Payments
$768.99
29 reported records · 9 companies
Healthcare provider profile · identity verified
Gretchen Davis, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LEES SUMMIT, MO · NPI 1891182267
Verified facts
What the public records show
CMS Open Payments records show Gretchen Davis, FNP-C received $768.99 in general payments during 2025 across 29 reported records.
Viatris Specialty LLC accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $291.11 | 37.9% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $158.27 | 20.6% | 9 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $100.89 | 13.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.67 | 10.9% | 3 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $40.67 | 5.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $26.97 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.72 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.32 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.37 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $768.99 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $291.11 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $282.61 | 13 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $100.89 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 252 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 36 |
| Tramadol Hcl | Tramadol Hcl | 195 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 28 |
| Gabapentin | Gabapentin | 138 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 17 |
| Divalproex Sodium | Divalproex Sodium | 123 | 32 |
| Buspirone Hcl | Buspirone Hcl | 117 | 31 |
| Memantine Hcl | Memantine Hcl | 116 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 108 | 18 |
| Baclofen | Baclofen | 106 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 15 |
| Famotidine | Famotidine | 96 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 18 |
| Alprazolam | Alprazolam | 91 | 19 |
| Furosemide | Furosemide | 91 | 23 |
| Donepezil Hcl | Donepezil Hcl | 90 | 15 |
| Potassium Chloride | Potassium Chloride | 89 | 18 |
| Bumetanide | Bumetanide | 87 | 20 |
| Sertraline Hcl | Sertraline Hcl | 77 | 16 |
| Losartan Potassium | Losartan Potassium | 71 | 11 |
| Lorazepam | Lorazepam | 70 | 19 |
| Spironolactone | Spironolactone | 64 | 14 |
| Lisinopril | Lisinopril | 63 | 13 |
| Eliquis | Apixaban | 60 | suppressed |
| Metformin Hcl | Metformin Hcl | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | suppressed |
| Risperidone | Risperidone | 55 | suppressed |
| Carvedilol | Carvedilol | 47 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 20 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 11 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 31 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Prednisone | Prednisone | 34 | 22 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 22 |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Metolazone | Metolazone | 24 | 12 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Omeprazole | Omeprazole | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Cefdinir | Cefdinir | 18 | 16 |
| Nystatin | Nystatin | 18 | 15 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $768.99 · 29 records | Viatris Specialty LLC | COBENFY, GVOKE HYPOPEN, Kerendia, NUPLAZID, REXULTI, The Cologuard Plus Collection Kit, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error